OKYO Pharma (OKYO) Liabilities and Shareholders Equity (2021 - 2026)

OKYO Pharma (OKYO) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $21.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 470.42% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $32.1 million (up 208.18% YoY), while the FY2026 annual figure was $21.0 million, up 470.42% from the prior year.
• Liabilities and Shareholders Equity improved to $21.0 million in Q1 2026 per OKYO's latest filing, from $4.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $21.0 million in Q1 2026 and bottomed at $1.5 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $5.7 million across 5 years, with a median of $4.0 million in 2022.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity tumbled 70.38% — and 2026, when it jumped 470.42%.
• OKYO Pharma's Liabilities and Shareholders Equity stood at $4.3 million in 2022, then slumped by 44.72% to $2.4 million in 2023, then gained by 19.0% to $2.8 million in 2024, then surged by 64.16% to $4.6 million in 2025, then soared by 351.7% to $21.0 million in 2026.
• Business Quant data shows OKYO's Liabilities and Shareholders Equity at $21.0 million in Q1 2026, $4.6 million in Q3 2025, and $3.7 million in Q1 2025.